BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24989170)

  • 1. Update on the development of enterovirus 71 vaccines.
    Kung YA; Hung CT; Liu YC; Shih SR
    Expert Opin Biol Ther; 2014 Oct; 14(10):1455-64. PubMed ID: 24989170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of enterovirus 71 vaccines.
    Lee MS; Chang LY
    Expert Rev Vaccines; 2010 Feb; 9(2):149-56. PubMed ID: 20109026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterovirus 71 vaccine: close but still far.
    Zhang D; Lu J; Lu J
    Int J Infect Dis; 2010 Sep; 14(9):e739-43. PubMed ID: 20400350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials.
    Li JX; Mao QY; Liang ZL; Ji H; Zhu FC
    Expert Rev Vaccines; 2014 May; 13(5):609-18. PubMed ID: 24621093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress on the research and development of inactivated EV71 whole-virus vaccines.
    Liang ZL; Mao QY; Wang YP; Zhu FC; Li JX; Yao X; Gao F; Wu X; Xu M; Wang JZ
    Hum Vaccin Immunother; 2013 Aug; 9(8):1701-5. PubMed ID: 23744508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EV71: an emerging infectious disease vaccine target in the Far East?
    Xu J; Qian Y; Wang S; Serrano JM; Li W; Huang Z; Lu S
    Vaccine; 2010 Apr; 28(20):3516-21. PubMed ID: 20304038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
    Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
    Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An overview of the evolution of EV71 vaccine].
    Li M; Yin Y; Li J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Aug; 27(4):933-6. PubMed ID: 20842875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.
    Sun S; Gao F; Mao Q; Shao J; Jiang L; Liu D; Wang Y; Yao X; Wu X; Sun B; Zhao D; Ma Y; Lu J; Kong W; Jiang C; Liang Z
    Hum Vaccin Immunother; 2015; 11(10):2406-13. PubMed ID: 26036916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of EV71 vaccine candidates.
    Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
    Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.
    Wang X; Dong K; Long M; Lin F; Gao Z; Wang L; Zhang Z; Chen X; Dai Y; Wang H; Zhang H
    Arch Virol; 2018 Jul; 163(7):1851-1861. PubMed ID: 29582164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.
    Zhou Y; Li JX; Jin PF; Wang YX; Zhu FC
    Expert Rev Vaccines; 2016 Jul; 15(7):803-13. PubMed ID: 27206811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
    Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
    Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
    Wang X; Ku Z; Zhang X; Ye X; Chen J; Liu Q; Zhang W; Zhang C; Fu Z; Jin X; Cong Y; Huang Z
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29070691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
    In HJ; Lim H; Lee JA; Lee SR; Jin YB; Jeong KJ; Hyeon JY; Yoo JS; Lee JW; Choi YK; Lee SW
    PLoS One; 2018; 13(10):e0202552. PubMed ID: 30278051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
    Liu CC; Chow YH; Chong P; Klein M
    Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of enterovirus 71 vaccines.
    Chong P; Liu CC; Chow YH; Chou AH; Klein M
    Clin Infect Dis; 2015 Mar; 60(5):797-803. PubMed ID: 25352588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus.
    Wu CN; Lin YC; Fann C; Liao NS; Shih SR; Ho MS
    Vaccine; 2001 Dec; 20(5-6):895-904. PubMed ID: 11738755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.
    Wang KT; Lin SJ; Wang HC; Chen PC; Lin JJ; Chiang JR; Chang CL; Shih DY; Lo CF; Wang DY
    Biologicals; 2016 Jul; 44(4):183-190. PubMed ID: 27068365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment.
    Ch'ng WC; Stanbridge EJ; Ong KC; Wong KT; Yusoff K; Shafee N
    J Med Virol; 2011 Oct; 83(10):1783-91. PubMed ID: 21837796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.